Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Diagnosis (Kidney Biopsy and Creatine Test)
1.2.3 Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
1.3 Market by Application
1.3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Perspective (2018-2033)
2.2 Focal Segmental Glomerulosclerosis (FSGS) Growth Trends by Region
2.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Focal Segmental Glomerulosclerosis (FSGS) Historic Market Size by Region (2018-2023)
2.2.3 Focal Segmental Glomerulosclerosis (FSGS) Forecasted Market Size by Region (2024-2033)
2.3 Focal Segmental Glomerulosclerosis (FSGS) Market Dynamics
2.3.1 Focal Segmental Glomerulosclerosis (FSGS) Industry Trends
2.3.2 Focal Segmental Glomerulosclerosis (FSGS) Market Drivers
2.3.3 Focal Segmental Glomerulosclerosis (FSGS) Market Challenges
2.3.4 Focal Segmental Glomerulosclerosis (FSGS) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Players by Revenue
3.1.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Players by Revenue (2018-2023)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Players (2018-2023)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Focal Segmental Glomerulosclerosis (FSGS) Revenue
3.4 Global Focal Segmental Glomerulosclerosis (FSGS) Market Concentration Ratio
3.4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Focal Segmental Glomerulosclerosis (FSGS) Revenue in 2022
3.5 Focal Segmental Glomerulosclerosis (FSGS) Key Players Head office and Area Served
3.6 Key Players Focal Segmental Glomerulosclerosis (FSGS) Product Solution and Service
3.7 Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Focal Segmental Glomerulosclerosis (FSGS) Breakdown Data by Type
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Historic Market Size by Type (2018-2023)
4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Forecasted Market Size by Type (2024-2033)
5 Focal Segmental Glomerulosclerosis (FSGS) Breakdown Data by Application
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Historic Market Size by Application (2018-2023)
5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size (2018-2033)
6.2 North America Focal Segmental Glomerulosclerosis (FSGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023)
6.4 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size (2018-2033)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023)
7.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size (2018-2033)
8.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (2018-2023)
8.4 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size (2018-2033)
9.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023)
9.4 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size (2018-2033)
10.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023)
10.4 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Travere Therapeutics (Retrophin)
11.1.1 Travere Therapeutics (Retrophin) Company Detail
11.1.2 Travere Therapeutics (Retrophin) Business Overview
11.1.3 Travere Therapeutics (Retrophin) Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.1.4 Travere Therapeutics (Retrophin) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.1.5 Travere Therapeutics (Retrophin) Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.2.4 Novartis Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 ZyVersa(Variant)
11.3.1 ZyVersa(Variant) Company Detail
11.3.2 ZyVersa(Variant) Business Overview
11.3.3 ZyVersa(Variant) Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.3.4 ZyVersa(Variant) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.3.5 ZyVersa(Variant) Recent Development
11.4 Dimerix
11.4.1 Dimerix Company Detail
11.4.2 Dimerix Business Overview
11.4.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.4.4 Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.4.5 Dimerix Recent Development
11.5 Goldfinch Bio
11.5.1 Goldfinch Bio Company Detail
11.5.2 Goldfinch Bio Business Overview
11.5.3 Goldfinch Bio Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.5.4 Goldfinch Bio Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.5.5 Goldfinch Bio Recent Development
11.6 ChemoCentryx
11.6.1 ChemoCentryx Company Detail
11.6.2 ChemoCentryx Business Overview
11.6.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.6.4 ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.6.5 ChemoCentryx Recent Development
11.7 FibroGen
11.7.1 FibroGen Company Detail
11.7.2 FibroGen Business Overview
11.7.3 FibroGen Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.7.4 FibroGen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.7.5 FibroGen Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.8.4 Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.9.4 AstraZeneca Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.9.5 AstraZeneca Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.10.4 Sanofi Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.10.5 Sanofi Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.11.4 GlaxoSmithKline Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.11.5 GlaxoSmithKline Recent Development
11.12 Calliditas
11.12.1 Calliditas Company Detail
11.12.2 Calliditas Business Overview
11.12.3 Calliditas Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.12.4 Calliditas Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.12.5 Calliditas Recent Development
11.13 Reata (AbbVie)
11.13.1 Reata (AbbVie) Company Detail
11.13.2 Reata (AbbVie) Business Overview
11.13.3 Reata (AbbVie) Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.13.4 Reata (AbbVie) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.13.5 Reata (AbbVie) Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Detail
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.14.4 Astellas Pharma Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.14.5 Astellas Pharma Recent Development
11.15 Complexa
11.15.1 Complexa Company Detail
11.15.2 Complexa Business Overview
11.15.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.15.4 Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.15.5 Complexa Recent Development
11.16 Aurinia
11.16.1 Aurinia Company Detail
11.16.2 Aurinia Business Overview
11.16.3 Aurinia Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.16.4 Aurinia Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.16.5 Aurinia Recent Development
11.17 Vertex Pharmaceuticals
11.17.1 Vertex Pharmaceuticals Company Detail
11.17.2 Vertex Pharmaceuticals Business Overview
11.17.3 Vertex Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.17.4 Vertex Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.17.5 Vertex Pharmaceuticals Recent Development
11.18 Chinook Therapeutics
11.18.1 Chinook Therapeutics Company Detail
11.18.2 Chinook Therapeutics Business Overview
11.18.3 Chinook Therapeutics Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.18.4 Chinook Therapeutics Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.18.5 Chinook Therapeutics Recent Development
11.19 Delta 4
11.19.1 Delta 4 Company Detail
11.19.2 Delta 4 Business Overview
11.19.3 Delta 4 Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.19.4 Delta 4 Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.19.5 Delta 4 Recent Development
11.20 Langlai Science and Technology
11.20.1 Langlai Science and Technology Company Detail
11.20.2 Langlai Science and Technology Business Overview
11.20.3 Langlai Science and Technology Focal Segmental Glomerulosclerosis (FSGS) Introduction
11.20.4 Langlai Science and Technology Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
11.20.5 Langlai Science and Technology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Diagnosis (Kidney Biopsy and Creatine Test)
Table 3. Key Players of Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
Table 4. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Region (2018-2023)
Table 8. Global Focal Segmental Glomerulosclerosis (FSGS) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Region (2024-2033)
Table 10. Focal Segmental Glomerulosclerosis (FSGS) Market Trends
Table 11. Focal Segmental Glomerulosclerosis (FSGS) Market Drivers
Table 12. Focal Segmental Glomerulosclerosis (FSGS) Market Challenges
Table 13. Focal Segmental Glomerulosclerosis (FSGS) Market Restraints
Table 14. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Players (2018-2023)
Table 16. Global Top Focal Segmental Glomerulosclerosis (FSGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) as of 2022)
Table 17. Ranking of Global Top Focal Segmental Glomerulosclerosis (FSGS) Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Focal Segmental Glomerulosclerosis (FSGS) Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Focal Segmental Glomerulosclerosis (FSGS) Product Solution and Service
Table 21. Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Type (2018-2023)
Table 25. Global Focal Segmental Glomerulosclerosis (FSGS) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Type (2024-2033)
Table 27. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Application (2018-2023)
Table 29. Global Focal Segmental Glomerulosclerosis (FSGS) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Application (2024-2033)
Table 31. North America Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size by Country (2024-2033) & (US$ Million)
Table 46. Travere Therapeutics (Retrophin) Company Detail
Table 47. Travere Therapeutics (Retrophin) Business Overview
Table 48. Travere Therapeutics (Retrophin) Focal Segmental Glomerulosclerosis (FSGS) Product
Table 49. Travere Therapeutics (Retrophin) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 50. Travere Therapeutics (Retrophin) Recent Development
Table 51. Novartis Company Detail
Table 52. Novartis Business Overview
Table 53. Novartis Focal Segmental Glomerulosclerosis (FSGS) Product
Table 54. Novartis Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. ZyVersa(Variant) Company Detail
Table 57. ZyVersa(Variant) Business Overview
Table 58. ZyVersa(Variant) Focal Segmental Glomerulosclerosis (FSGS) Product
Table 59. ZyVersa(Variant) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 60. ZyVersa(Variant) Recent Development
Table 61. Dimerix Company Detail
Table 62. Dimerix Business Overview
Table 63. Dimerix Focal Segmental Glomerulosclerosis (FSGS) Product
Table 64. Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 65. Dimerix Recent Development
Table 66. Goldfinch Bio Company Detail
Table 67. Goldfinch Bio Business Overview
Table 68. Goldfinch Bio Focal Segmental Glomerulosclerosis (FSGS) Product
Table 69. Goldfinch Bio Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 70. Goldfinch Bio Recent Development
Table 71. ChemoCentryx Company Detail
Table 72. ChemoCentryx Business Overview
Table 73. ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Product
Table 74. ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 75. ChemoCentryx Recent Development
Table 76. FibroGen Company Detail
Table 77. FibroGen Business Overview
Table 78. FibroGen Focal Segmental Glomerulosclerosis (FSGS) Product
Table 79. FibroGen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 80. FibroGen Recent Development
Table 81. Pfizer Company Detail
Table 82. Pfizer Business Overview
Table 83. Pfizer Focal Segmental Glomerulosclerosis (FSGS) Product
Table 84. Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 85. Pfizer Recent Development
Table 86. AstraZeneca Company Detail
Table 87. AstraZeneca Business Overview
Table 88. AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Product
Table 89. AstraZeneca Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 90. AstraZeneca Recent Development
Table 91. Sanofi Company Detail
Table 92. Sanofi Business Overview
Table 93. Sanofi Focal Segmental Glomerulosclerosis (FSGS) Product
Table 94. Sanofi Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 95. Sanofi Recent Development
Table 96. GlaxoSmithKline Company Detail
Table 97. GlaxoSmithKline Business Overview
Table 98. GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Product
Table 99. GlaxoSmithKline Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 100. GlaxoSmithKline Recent Development
Table 101. Calliditas Company Detail
Table 102. Calliditas Business Overview
Table 103. Calliditas Focal Segmental Glomerulosclerosis (FSGS) Product
Table 104. Calliditas Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 105. Calliditas Recent Development
Table 106. Reata (AbbVie) Company Detail
Table 107. Reata (AbbVie) Business Overview
Table 108. Reata (AbbVie) Focal Segmental Glomerulosclerosis (FSGS) Product
Table 109. Reata (AbbVie) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 110. Reata (AbbVie) Recent Development
Table 111. Astellas Pharma Company Detail
Table 112. Astellas Pharma Business Overview
Table 113. Astellas Pharma Focal Segmental Glomerulosclerosis (FSGS) Product
Table 114. Astellas Pharma Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 115. Astellas Pharma Recent Development
Table 116. Complexa Company Detail
Table 117. Complexa Business Overview
Table 118. Complexa Focal Segmental Glomerulosclerosis (FSGS) Product
Table 119. Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 120. Complexa Recent Development
Table 121. Aurinia Company Detail
Table 122. Aurinia Business Overview
Table 123. Aurinia Focal Segmental Glomerulosclerosis (FSGS) Product
Table 124. Aurinia Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 125. Aurinia Recent Development
Table 126. Vertex Pharmaceuticals Company Detail
Table 127. Vertex Pharmaceuticals Business Overview
Table 128. Vertex Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Product
Table 129. Vertex Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 130. Vertex Pharmaceuticals Recent Development
Table 131. Chinook Therapeutics Company Detail
Table 132. Chinook Therapeutics Business Overview
Table 133. Chinook Therapeutics Focal Segmental Glomerulosclerosis (FSGS) Product
Table 134. Chinook Therapeutics Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 135. Chinook Therapeutics Recent Development
Table 136. Delta 4 Company Detail
Table 137. Delta 4 Business Overview
Table 138. Delta 4 Focal Segmental Glomerulosclerosis (FSGS) Product
Table 139. Delta 4 Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 140. Delta 4 Recent Development
Table 141. Langlai Science and Technology Company Detail
Table 142. Langlai Science and Technology Business Overview
Table 143. Langlai Science and Technology Focal Segmental Glomerulosclerosis (FSGS) Product
Table 144. Langlai Science and Technology Revenue in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023) & (US$ Million)
Table 145. Langlai Science and Technology Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Type: 2022 VS 2033
Figure 3. Diagnosis (Kidney Biopsy and Creatine Test) Features
Figure 4. Treatment (Drug Therapy, Dialysis, and Kidney Transplant) Features
Figure 5. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application: 2022 VS 2033
Figure 7. Hospitals Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Specialty Clinics Case Studies
Figure 10. Focal Segmental Glomerulosclerosis (FSGS) Report Years Considered
Figure 11. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Region: 2022 VS 2033
Figure 14. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Players in 2022
Figure 15. Global Top Focal Segmental Glomerulosclerosis (FSGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Focal Segmental Glomerulosclerosis (FSGS) Revenue in 2022
Figure 17. North America Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Focal Segmental Glomerulosclerosis (FSGS) Market Share by Country (2018-2033)
Figure 19. United States Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Share by Country (2018-2033)
Figure 23. Germany Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Share by Region (2018-2033)
Figure 31. China Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Share by Country (2018-2033)
Figure 39. Mexico Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Market Share by Country (2018-2033)
Figure 43. Turkey Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Focal Segmental Glomerulosclerosis (FSGS) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Travere Therapeutics (Retrophin) Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 46. Novartis Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 47. ZyVersa(Variant) Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 48. Dimerix Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 49. Goldfinch Bio Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 50. ChemoCentryx Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 51. FibroGen Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 53. AstraZeneca Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 54. Sanofi Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 56. Calliditas Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 57. Reata (AbbVie) Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 58. Astellas Pharma Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 59. Complexa Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 60. Aurinia Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 62. Chinook Therapeutics Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 63. Delta 4 Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 64. Langlai Science and Technology Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed